Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins and Other Symptomatic Venous Disorders
Defines medical necessity, clinical criteria, contraindications, and coding guidance for sclerotherapy and chemical endovenous ablation (including cyanoacrylate) for treatment of varicose veins and other symptomatic venous disorders for Centene-affiliated health plans.
Added CPT codes 36482 and 36483 (cyanoacrylate endovenous ablation) to the table of codes that support medical necessity.
Clarified that cyanoacrylate adhesive (VenaSeal) when requested is for the small saphenous vein (and elsewhere includes the great saphenous vein in specific criteria revisions).
Added requirement for documentation of symptomatic venous disorder of CEAP class C2 or greater.
Added ultrasound documentation requirements (duplex ultrasound evaluation and specific performance elements).
Added criteria requiring documentation of symptomatic CEAP Class 2 or greater.
Updated duplex ultrasound reflux thresholds to > 500 milliseconds and perforator diameter to > 3.5 mm where applicable.
Specified that cyanoacrylate adhesive (VenaSeal) requests are for the small saphenous vein only (previously clarified/changed over time).
Added CPT codes 36482 and 36483 to the list of codes that support medical necessity.
Removed requirement for documented lidocaine allergy from a specific criterion (ID.2).
Coverage Criteria
inv-01: Initial therapy / Medical necessity criteria
Covered when ALL of the following are met:
Root
- A. Clinical severity: Documentation of symptomatic venous disorder of CEAP class C2 or greater
See CEAP classification (Table 1) and policy for examples of C2+ conditions
- B. Duplex ultrasound documentation: Duplex ultrasound demonstrating venous reflux or perforator abnormality meeting policy thresholds (eg, axial reflux > 500 milliseconds and vein diameter ≥ 3 mm in great saphenous or accessory veins; reflux > 500 milliseconds and diameter ≥ 3 mm in small saphenous vein; perforating vein reflux with diameter > 3.5 mm for veins beneath healed or open ulcers)
Ultrasound performed per guideline elements; images/reports may be requested
- C. Complications or symptoms: Presence of complications attributed to venous reflux (ulceration, superficial thrombophlebitis, hemorrhage or recurrent bleeding from ruptured varicosity/telangiectasia) OR severe, persistent pain or swelling that interferes with daily life despite at least 6 weeks of conservative therapy6 weeks of conservative therapy unless contraindicated
Conservative measures include compression therapy, limb elevation, ambulation, avoiding prolonged sitting/standing
- D. Contraindications absent: None of the listed contraindications are present (examples: previous sclerotherapy in same vein < 6 weeks; pregnancy or within 3 months postpartum; allergy to sclerosant; acute infection or acute DVT; severe distal arterial disease/critical limb ischemia or ABI ≤ 0.4; obliteration of deep venous system; tortuosity preventing catheter placement; requirement of vein for bypass; Klippel-Trenaunay syndrome; prolonged immobility)
Full contraindication list available in policy
- E. Cyanoacrylate-specific: If cyanoacrylate adhesive (eg, VenaSeal) is requested, the treatment must be for the small saphenous vein (policy history clarifies VenaSeal use and prior iterations)
See policy revisions for additional context on cyanoacrylate use
Photographic and/or ultrasound images may be requested
inv-02: Initial therapy / coverage criteria (summary)
Covered when ALL of the following updated criteria are met (high-level summary from revisions in this document window):
Full policy contains expanded lists of indications, contraindications, duplex performance elements, and documentation requirements; photographic or ultrasound images may be requested to support documentation.
Asymptomatic varicose veins — including superficial reticular veins and telangiectasias — are not supported indications for sclerotherapy or chemical endovenous ablation under this policy. Treatment requests should document symptomatic disease meeting the policy’s clinical severity requirements (eg, CEAP Class C2 or greater) in order to be considered for coverage.
The policy revision history removed prior blanket language that cyanoacrylate adhesive (eg, VenaSeal) was not medically necessary. Current policy language instead restricts requests for cyanoacrylate endovenous adhesive to treatment of the small saphenous vein only unless other specific criteria apply, and the document now includes CPT codes 36482 and 36483 as codes that support medical necessity when the coverage criteria are met.
The policy states there is insufficient evidence to support sclerotherapy for indications other than those explicitly specified in the coverage criteria. Historical wording that labeled procedures as "experimental/investigational" was replaced with descriptive language, but unsupported indications remain not covered unless they meet the policy’s stated criteria and documentation requirements.
Earlier policy language that explicitly listed cyanoacrylate adhesive as not medically necessary was removed during revision. The current document no longer contains that blanket NMN statement and instead provides clarified, limited guidance on cyanoacrylate use (see restriction to the small saphenous vein and the addition of CPT codes 36482 and 36483 to supporting codes). The portion shown does not enumerate other explicit NMN listings beyond the unsupported indications referenced elsewhere in the policy.
Coding and Codes Supporting Medical Necessity
| 36465 | Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein) |
| 36466 | Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins, same leg |
| 36470 | Injection of sclerosant; single incompetent vein (other than telangiectasia) |
| 36471 | Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg |
| 36482 | Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate), remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated |
| 36483 | Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites |
| 36482 | Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate), remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated |
| 36483 | Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization is required for procedures coded with the listed CPT codes. Providers should obtain prior authorization and ensure submitted claims include the supporting clinical documentation described below. Codes that support medical necessity include those for sclerotherapy, foam sclerosant injection, and chemical endovenous ablation (including cyanoacrylate adhesive delivery).
Triggers for Denial
Failure to provide the required clinical documentation or imaging, or failure to meet the ultrasound parameters and clinical thresholds described in policy, are common triggers for denial. Claims may also be denied when contraindications are present or when conservative therapy requirements have not been met where specified.
- Denial triggers include: lack of documentation of symptomatic CEAP Class 2 (C2) or greater; absent or inadequate duplex ultrasound documentation (see required parameters); failure to document prior conservative therapy when required; presence of listed contraindications (eg, pregnancy within 3 months, acute infection, severe peripheral arterial disease, obliterated deep venous system, recent sclerotherapy in same vein <6 weeks, etc.)
- Claims for cyanoacrylate procedures may be denied if requested for indications outside the policy constraints (eg, not the approved vein when restricted)
Documentation and Imaging Requirements
Providers must submit adequate clinical and imaging documentation with prior authorization requests and claims to support medical necessity. Photographic documentation and/or full duplex ultrasound images/reports may be requested to corroborate the written record.
- Required clinical documentation: documentation of symptomatic venous disorder meeting CEAP Clinical Class C2 or greater and the Revised Venous Clinical Severity Score (r‑VCSS) when specified (eg, r‑VCSS ≥ 6 when required by criteria)
- Required imaging: duplex ultrasound report and, when requested, saved images demonstrating reflux and measurements per policy (see ultrasound parameter thresholds below)
- Operational note: photographic documentation of the affected limb and ultrasound images may be requested to support the written documentation
Required Documentation
Specific documentation elements must be present in the medical record and submitted with authorization requests: CEAP classification, r‑VCSS (when required), duplex ultrasound findings with quantitative parameters, and a record of conservative therapy when required.
- CEAP: documentation that the member/enrollee is symptomatic with Clinical Class ≥ C2
- r‑VCSS: include score when the policy criteria call for it (eg, r‑VCSS ≥ 6 where specified)
- Duplex ultrasound: include vein(s) evaluated, measured vein diameters, measured reflux times, and whether testing was performed standing when possible; save and submit images if requested
- Conservative therapy documentation: when required, document at least six weeks of conservative measures (compression therapy, limb elevation, avoidance of prolonged sitting/standing, and ambulation) unless contraindicated
Required Clinical Documentation
Clinical indication for the procedure must be clearly stated and meet policy clinical criteria prior to authorization or payment. The request should explain how the member's signs/symptoms meet thresholds and why intervention is indicated.
- State symptomatic CEAP Class (C2 or greater) and relevant complications (eg, ulceration, recurrent bleeding, severe persistent swelling affecting daily life)
- Provide specific duplex ultrasound parameters meeting policy thresholds (examples below): reflux > 500 milliseconds for axial or perforator reflux; perforator diameter > 3.5 mm; axial reflux and diameter thresholds for great/small saphenous veins as specified
- If treating recurrent varicosities, document prior evaluation and reason for retreatment; avoid retreatment of the same area within six to eight weeks of prior effective treatment
Conservative Therapy Context
Conservative management is expected prior to intervention in many instances. Document attempts and duration of conservative measures or note contraindications to these measures.
- Conservative therapy generally includes at least six weeks of: compression therapy, limb elevation, avoidance of prolonged sitting/standing, and ambulation as tolerated
- If conservative therapy is not appropriate or contraindicated (eg, active ulcer with perforator directly beneath, or other contraindications), document the reason(s) and relevant clinical findings
- Policy allows exceptions when specified (for example, perforating vein located beneath an open venous ulcer may meet criteria without a preceding six‑week conservative trial if other criteria are satisfied)
Definitions
Background
Varicose veins are dilated lower‑extremity veins frequently associated with chronic venous insufficiency and venous reflux that may produce pain, swelling, bleeding, superficial thrombophlebitis, or ulceration. Minimally invasive treatments addressed by this policy include sclerotherapy (liquid or foam injection of a sclerosant) and chemical endovenous ablation with cyanoacrylate adhesive (eg, VenaSeal). Duplex ultrasound assessment of venous reflux and documentation of symptomatic disease (eg, CEAP Class C2 or greater) are required elements for evaluation and coverage consideration per the updated criteria and guideline references.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.